Chronic diastolic (congestive) heart failure
Methodology & AI Transparency ⓘ
Chronic diastolic (congestive) heart failure Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code I50.32 in Heart & Vascular, Chronic diastolic (congestive) heart failure requires coronary perfusion imaging [Chronic diastolic (congestive) heart failure I50.32] so specialists can calibrate treatment intensity against High-Sensitivity Troponin I [Chronic diastolic (congestive) heart failure I50.32] benchmarks.
- 2 Real-world patient consensus: Diagnostic registry I50.32: Chronic diastolic (congestive) heart failure is managed within Heart & Vascular.
- 3 Typical cash cost range: Differential triage of Chronic diastolic (congestive) heart failure (I50.32) utilizes coronary perfusion imaging [Chronic diastolic (congestive) heart failure I50.32].
- 4 Top reported side effects / signs: Objective lab/clinical target for Chronic diastolic (congestive) heart failure: High-Sensitivity Troponin I [Chronic diastolic (congestive) heart failure I50.32] (< 14 ng/L (I50.32)) and Apolipoprotein B (ApoB) [Chronic diastolic (congestive) heart failure I50.32].
Ask our AI Specialists anything about Chronic diastolic (congestive) heart failure
What Is Chronic diastolic (congestive) heart failure?
Cataloged under federal diagnostic code I50.32 in Heart & Vascular, Chronic diastolic (congestive) heart failure requires coronary perfusion imaging [Chronic diastolic (congestive) heart failure I50.32] so specialists can calibrate treatment intensity against High-Sensitivity Troponin I [Chronic diastolic (congestive) heart failure I50.32] benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Chronic diastolic (congestive) heart failure (ICD-10 I50.32) is driven by fibrotic extracellular matrix in Chronic diastolic (congestive) heart failure (I50.32: deposition); specialists in Heart & Cardiovascular Disease monitor Apolipoprotein B (ApoB) [Chronic diastolic (congestive) heart failure I50.32] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Chronic diastolic (congestive) heart failure (I50.32): shortness of breath in Chronic diastolic (congestive) heart failure (I50.32: when climbing stairs)
- • Secondary Chronic diastolic (congestive) heart failure clinical sign: palpitations, skipped beats, in Chronic diastolic (congestive) heart failure (I50.32: or irregular resting)
- • Symptom flares in Chronic diastolic (congestive) heart failure correlating with High-Sensitivity Troponin I [Chronic diastolic (congestive) heart failure I50.32] deviation outside < 14 ng/L (I50.32)
- • Functional heart & vascular impact requiring coronary perfusion imaging [Chronic diastolic (congestive) heart failure I50.32] evaluation (I50.32)
Chronic diastolic (congestive) heart failure Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I50.32 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Chronic diastolic (congestive) heart failure I50.32] | < 14 ng/L (I50.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Chronic diastolic (congestive) heart failure I50.32] | < 70 mg/dL (I50.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Chronic diastolic (congestive) heart failure (I50.32: Fraction (LVEF)) | 55% – 70% (I50.32) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chronic diastolic (congestive) heart failure
Treatment selection for Chronic diastolic (congestive) heart failure depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chronic diastolic (congestive) heart failure)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
Chronic diastolic (congestive) heart failure Patient Community & “People Like Me” Threads
Filter Chronic diastolic (congestive) heart failure community threads and patient logs by age, biological sex, dosage, and treatment duration.